drugset / Trial / NCT03479476
A Trial of Metformin in Individuals With Fragile X Syndrome
Phase 2/3
Completed
120 enrolled
University of California, Davis
St. Justine's Hospital · collabUniversity of Alberta · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.
Timeline
- Start
- 2018-04-30
- Primary completion
- 2024-05-22
- Completion
- 2024-05-22